From lifespan extension to hallmark-informed gerotherapeutic prioritization: A bibliometric-guided, strategy-oriented review of anti-aging drug research.
Key claim: A bibliometric-guided review maps anti-aging drug research onto three overlapping axes—senotherapeutics, nutrient-sensing/metabolic gerotherapeutics, and homeostasis-restoring agents—and uses that map to prioritize candidate gerotherapeutics for precision geromedicine.
Abstract
Anti-aging pharmacology has transitioned from early exploratory lifespan-extension studies to a hallmark-informed, multi-level framework that integrates mechanistic, preclinical, and translational evidence. Using a bibliometric-guided, strategy-oriented approach, this review maps the explicit anti-aging drug literature from 2005 to 2025, identifies historically influential compounds, and evaluates their translational readiness. The field converges on three partially overlapping intervention axes: senotherapeutics targeting cellular senescence and SASP signaling, nutrient-sensing and metabolic gerotherapeutics modulating mTOR, AMPK, autophagy, and mitochondrial adaptation, and homeostasis-restoring agents reinforcing redox, inflammatory, and circadian resilience. The Top 10 anchors, prioritized by bibliometric prominence rather than clinical ranking, illustrate both potential and limitations in human translation, while emerging candidates and platform innovations highlight ongoing progress toward precision geromedicine. This synthesis provides a structured framework for interpreting historical and contemporary literature, clarifies the relationship between multi-hallmark engagement and functional outcomes, and guides rational prioritization of candidate gerotherapeutics for future research.
Why this matters
The ‘precision geromedicine’ label is accumulating conceptual scaffolding — first a feasibility trial protocol, now a bibliometric map organizing the drug landscape into three intervention axes — but the underlying evidence base for prioritizing any specific gerotherapeutic remains review-level synthesis rather than outcome data. Tracking these framework papers matters because they shape which molecules clinics and influencers will foreground next, even as the translational evidence stays thin.